David J. Andorsky, MD, discusses the results of a subgroup analysis of the phase 3b MAGNIFY trial in relapsed/refractory non-Hodgkin lymphoma.
David J. Andorsky, MD, medical oncologist/hematologist, Rocky Mountain Cancer Centers, discusses the results of a subgroup analysis of the phase 3b MAGNIFY trial in relapsed/refractory non-Hodgkin lymphoma (NHL).
The MAGNIFY trial evaluated induction rituximab (Rituxan) plus lenalidomide (Revlimid; R2) followed by lenalidomide versus rituximab maintenance therapy for patients with relapsed/refractory follicular lymphoma, marginal zone lymphoma, or mantle cell lymphoma. During the 2020 ASH Annual Meeting & Exposition, findings from subgroup analyses of the MAGNIFY trial were presented virtually and showed similar responses in elderly patients aged 70 or older and younger patients, says Andorsky.
Patients within the older population were a median age of 76; 29% of patients were 80 years or older, explains Andorsky. Additionally, older patients had lower incidences of high-risk features and early relapse compared with the general population.
The overall response rate in the older and younger populations was 75%; the complete response rate was 39% in the older population and 47% in the younger population. The median progression-free survival was similar between groups, at 40.1 months and 41.6 months, respectively. Finally, the regimen was found to be well tolerated among older patients, with similar rates of neutropenia observed compared with the younger population, concludes Andorsky.